Fate Therapeutics Inc
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · San Diego, CA
FATE chart
What traders are saying about $FATE
Latest postsFate Therapeutics Inc news
- Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)
MarketBeat ·
- Fate Therapeutics Reports FT819 Lupus Kidney Responses
grafa.com ·
- Fate Therapeutics, Inc. (FATE) stock price, news, quote and history
Yahoo Finance Australia ·
- Fate Therapeutics, Inc. (FATE) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Fate Therapeutics presents updated FT819 data at Kidney Week
TipRanks ·
- Fate Therapeutics shares Phase 1 FT819 data for lupus nephritis
StreetInsider ·
- Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Yahoo Finance ·
- Two people with lupus kidney disease saw urine protein fall about 50% on average after Fate's cell therapy.
Stock Titan ·
- symbol__ Stock Quote Price and Forecast
CNN ·
- Fate Therapeutics, Inc. Estimates – NASDAQ:FATE
TradingView ·
- 1,165,927 Fate Therapeutics, Inc. $FATE Shares Bought by Assenagon Asset Management S.A.
MarketBeat ·
- Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Yahoo Finance ·
Fate Therapeutics Inc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M |
| Net income | -$136.3M | -$186.3M | -$160.9M | -$281.7M |
| Diluted EPS | $-1.15 | $-1.64 | $-1.64 | $-2.91 |
| Total assets (year end) | $318.9M | $440.7M | $506.2M | $705.6M |
| Cash and equivalents (year end) | $46.6M | $36.1M | $41.9M | $61.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Fate Therapeutics Inc
- Ticker
- FATE (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- SEC CIK
- 1434316
Frequently asked questions
What exchange is Fate Therapeutics Inc listed on?
Fate Therapeutics Inc trades on the Nasdaq under the ticker symbol FATE.
What industry is Fate Therapeutics Inc in?
Fate Therapeutics Inc is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Fate Therapeutics Inc headquartered?
Fate Therapeutics Inc's business address on file with the SEC is in San Diego, CA.
When does Fate Therapeutics Inc's fiscal year end?
Fate Therapeutics Inc's fiscal year ends on December 31.
How much revenue did Fate Therapeutics Inc report?
Fate Therapeutics Inc reported $6.6M in revenue for calendar year 2025, according to its SEC filings.